MSD Pharma inks pact to make investigational COVID-19 drugIllustrative image – not actual.
MSD Pharmaceuticals, a wholly-owned subsidiary of Merck Sharp & Dohme (MSD), has inked a pact with Indian generic manufacturers -- Sun Pharmaceutical Industries, Cipla, Dr Reddy’s Laboratories, Emcure Pharmaceuticals and Hetero Labs -- to contract manufacture the COVID-19 drug Molnupiravir.

The agreements are aimed at accelerating availability of Molnupiravir in India and in other low- and middle-income countries (LMICs) following approvals or emergency authorisation by local regulatory agencies. The company will soon approach the Drugs Controller General of India for a regulatory authorisation.

MSD is developing Molnupiravir in collaboration with Ridgeback Biotherapeutics. Under the agreements, Merck & Company will provide licenses to these manufacturers to supply Molnupiravir to India and more than 100 LMICs.

← All latest storiesBack to top →